Antithrombotic treatment in atrial fibrillation

Postgraduate Medical Journal

Volumn 84, Issue 991, 2008, Pages 252-258

  Lip, Gregory Y H ^a   Boos, C J ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CLOPIDOGREL; DIPYRIDAMOLE; IDRAPARINUX; INDOBUFEN; PHENPROCOUMON; PLACEBO; THROMBIN INHIBITOR; TRIFUSAL; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIAGNOSTIC TEST; DRUG DOSE COMPARISON; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROPHYLAXIS; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TREATMENT PLANNING;

ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; DRUG COMBINATIONS; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; STROKE; VITAMIN K; WARFARIN;

EID: 45249101621     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.066944     Document Type: Review

References (33)

1. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118-50.
2. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl):429S-56S.
3. Stewart S, Murphy N, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-92.
4. Freestone B, Lip GYH. Epidemiology and costs of cardiac arrhythmias. In: Lip GYH, Godtfredsen J, eds. Cardiac arrhythmias: a clinical approach. Edinburgh: Mosby, 2003:3-24.
5. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001;285:2370-5.
6. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003;108:711-6.
7. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation 1998;98:946-52.
8. Lip GYH, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 2005; doi: 10.1016/j.thromres.2005. 08.007.
9. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
10. Tsang TS, Petty GW, Barnes ME, et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol 2003;42:93-100.
11. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005;36:1115-9.
12. Kimura K, Minematsu K, Yamaguchi T. Japan Multicenter Stroke Investigators' Collaboration (J-MUSIC). Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry 2005;76:679-83.
13. Stager C, Pratter A, Martinek-Bregel M, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian stroke registry. Eur Heart J 2004;25:1734- 40.
14. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000;35:183-7.
15. Flaker GC, Belew K, Beckman K, et al. Asymptomatic atrial fibrillation: demographic features and prognostic information from the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Am Heart J 2005;149:657-63.
16. Manning WJ, Silverman DI, Waksmonski CA, et al. Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. Arch Intern Med 1995;155:2193-8.
17. Lip GYH. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995;346:1313-4.
18. Choudhury A, Lip GYH. Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice. Pathophysiol Haemost Thromb 2003/2004;33:282-9.
19. Wysokinski WE, Owen WG, Fass DN, et al. Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi. J Thromb Haemost 2004;2:1637-44.
20. Kamath S, Blann AD, Chin BS, et al. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol 2002;40:484-90.
21. Vene N, Mavri A, Kosmelj K, et al. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost 2003;90:1163-72.
22. Conway DS, Pearce LA, Chin BS, et al. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003;107:3141-5.
23. Iqbal MB, Taneja AK, Lip GYH, et al. Recent developments in atrial fibrillation BMJ 2005;330:238-43.
24. Chugh SS, Blackshear JL, Shen WK, et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001;37:371-8.
25. Lane D, Lip GYH. Anti-thrombotic therapy for atrial fibrillation and patients' preferences for treatment. Age Ageing 2005;34:1-3.
26. Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ 1999;318:1324-7.
27. Olsson SB. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-8.
28. SPORTIF Executive Committee for the SPORTIF V Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 2005;293:690-8.
29. Boos CJ, Hinton A, Lip GYH. Ximelagatran: a clinical perspective. Eur J Intern Med 2005;16:267-78.
30. Hohnloser SH, Connolly SJ. Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. J Cardiovasc Electrophysiol 2003;14:S60-3.
31. Diener HC, Bogousslavsky J, Brass LM, et al. MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-7.
32. Tan KT, Makin A, Lip GYH. Factor X inhibitors. Expert Opin Investig Drugs 2003;12:799-804.
33. Idraparinux sodium: SANORG SR 34006. Drugs R D 2004;5:164-5.